Exploiting epigenetic dependencies in ovarian cancer therapy

Abstract excerpt

Ovarian cancer therapy has remained fundamentally unchanged for 50 years, with surgery and chemotherapy still the frontline treatments. Typically asymptomatic until advanced stages, ovarian cancer is known as "the silent killer." Consequently, it has one of the worst 5-year survival rates, as low as 30%. The most frequent driver mutations are found in well-defined tumor suppressors, such as p53 and BRCA1/2. In...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Chromatin Remodeling and Cancer
• Share to Epigenetics and DNA Methylation